Resveratrol: A therapeutic approach to neurodegenerative diseases and aging

Mini-Reviews in Organic Chemistry

Volumn 7, Issue 4, 2010, Pages 267-271

  Pallas M ^a,b   Canudas, A M ^a,b   Junyent, F ^b,c   Jimenez, A ^a,b   Verdaguer, E ^a,b   Camins, A ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Cell cycle; Oxidative stress; Sirtuin 1

Indexed keywords

CELL DEATH; NEURODEGENERATIVE DISEASES;

BENEFICIAL EFFECTS; CARDIOVASCULAR DISEASE; CELL CYCLE; DISEASE MODELS; ISCHEMIC INJURIES; LIFESPANS; POLYPHENOLS; SIRTUIN; SIRTUIN 1; STRESS RESISTANCE;

RESVERATROL;

EID: 77958158511     PISSN: 1570193X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157019310792246391     Document Type: Article

References (59)

1. Baur, J. A., Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5(6), 493-506.
2. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., Pistell, P.J., Poosala, S., Becker, K.G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G., Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., de Cabo, R., Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444(7117), 337-342.
3. Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., Swindell, W.R., Kamara, D., Minor, R.K., Perez, E., Jamieson, H.A., Zhang, Y., Dunn, S.R., Sharma, K., Pleshko, N., Woollett, L.A., Csiszar, A., Ikeno, Y., Le Couteur, D., Elliott, P.J., Becker, K.G., Navas, P., Ingram, D.K., Wolf, N.S., Ungvari, Z., Sinclair, D.A., de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab., 2008, 8(2), 157-168.
4. Barger, J.L., Kayo, T., Vann, J.M., Arias, E.B., Wang, J., Hacker, T.A., Wang, Y., Raederstorff, D., Morrow, J.D., Leeuwenburgh, C., Allison, D.B., Saupe, K.W., Cartee, G.D., Weindruch, R., Prolla, T.A. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE, 2008, 3(6), e2264.
5. Fremont, L. Biological effects of resveratrol. Life Sci., 2000, 66(8), 663-673.
6. Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E., Jr., Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32(12), 1377-1382.
7. Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M.C., Obrador, E., Estrela, J.M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med., 2002, 33(3), 387-398.
8. Hsieh, T.C., Wang, Z., Hamby, C.V., Wu, J.M. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem. Biophys. Res. Commun., 2005, 334(1), 223-230.
9. Buryanovskyy, L., Fu, Y., Boyd, M., Ma, Y., Hsieh, T.C., Wu, J.M., Zhang, Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry, 2004, 43(36), 11417-11426.
10. Holvoet, P. Oxidized LDL and coronary heart disease. Acta Cardiol., 2004, 59(5), 479-484.
11. Turrens, J.F., Lariccia, J., Nair, M.G. Resveratrol has no effect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic. Res., 1997, 27(6), 557-562.
12. Renaud, S., de L.M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet, 1992, 339(8808), 1523-1526.
13. Afaq, F., Adhami, V.M., Ahmad, N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol., 2003, 186(1), 28-37.
14. Morales, A.I., Buitrago, J.M., Santiago, J.M., Fernandez-Tagarro, M., Lopez-Novoa, J.M., Perez-Barriocanal, F. Protective effect of trans-resveratrol on gentamicin-induced nephrotoxicity. Antioxid. Redox Signal., 2002, 4(6), 893-898.
15. Mizutani, K., Ikeda, K., Kawai, Y., Yamori, Y. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol., 2001, 28(1-2), 55-59.
16. Floreani, M., Napoli, E., Quintieri, L., Palatini, P. Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci., 2003, 72(24), 2741-2750.
17. Ferry-Dumazet, H., Garnier, O., Mamani-Matsuda, M., Vercauteren, J., Belloc, F., Billiard, C., Dupouy, M., Thiolat, D., Kolb, J.P., Marit, G., Reiffers, J., Mossalayi, M.D. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis, 2002, 23(8), 1327-1333.
18. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E.A., Caldwell, S.D., Napper, A., Curtis, R., DiStefano, P.S., Fields, S., Bedalov, A., Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280(17), 17038-17045.
19. Nemoto, S., Fergusson, M.M., Finkel, T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem., 2005, 280(16), 16456-16460.
20. Kumar, P., Padi, S.S., Naidu, P.S., Kumar, A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav. Pharmacol., 2006, 17(5-6), 485-492.
21. Parker, J.A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., Néri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet., 2005, 37(4), 349-350.
22. Borrell-Pages, M., Zala, D., Humbert, S., Saudou, F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol. Life Sci., 2006, 63(22), 2642-2660.
23. Tang, B.L., Chua, C.E.L. SIRT1 and neuronal diseases. Mol. Aspects. Med., 2008, 29(3), 187-200.
24. Anekonda, T.S. Resveratrol-a boon for treating Alzheimer's disease? Brain Res. Rev., 2006, 52(2), 316-326.
25. Anekonda, T.S., Reddy, P.H. Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res. Brain Res. Rev., 2005, 50(2), 361-376.
26. Hardy, J., Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
27. Pallas, M., Camins, A. Molecular and biochemical features in Alzheimer's disease. Curr. Pharm. Des., 2006, 12(33), 4389-4408.
28. Wirths, O., Multhaup, G., Bayer, T.A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J. Neurochem., 2004, 91(3), 513-520.
29. Cuello, A.C. Intracellular and extracellular Abeta, a tale of two neuropathologies. Brain Pathol., 2005, 15(1), 66-71.
30. Valerio, A., Boroni, F., Benarese, M., Sarnico, I., Ghisi, V., Bresciani, L.G., Ferrario, M., Borsani, G., Spano, P., Pizzi, M. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur. J. Neurosci., 2006, 23(7), 1711-1720.
31. Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.F., Kwon, H., Yi, S., Mucke, L., Gan, L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem., 2005, 280(48), 40364-40374.
32. Yeung, F., Hoberg, J.E., Ramsey, C.S., Keller, M.D., Jones, D.R., Frye, R.A., Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 2004, 23(12), 2369-2380.
33. Frank, B., Gupta, S. A review of antioxidants and Alzheimer's disease. Ann. Clin. Psychiatry, 2005, 17(4), 269-286.
34. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. FASEB J., 2003, 17(14), 1975-1985.
35. Mattson, M.P., Duan, W., Chan, S.L., Cheng, A., Haughey, N., Gary, D.S., Guo, Z., Lee, J., Furukawa, K. Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. Neurobiol. Aging, 2002, 23(5), 695-705.
36. Mattson, M.P. Will caloric restriction and folate protect against AD and PD? Neurology, 2003, 60(4), 690-695.
37. Patel, N.V., Gordon, M.N., Connor, K.E., Good, R.A., Engelman, R.W., Mason, J., Morgan, D.G., Morgan, T.E., Finch, C.E. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging, 2005, 26(7), 995-1000.
38. Wang, R., Wang, B., He, W., Zheng, H. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J. Biol. Chem., 2006, 281(22), 15330-15336.
39. Farris, W., Mansourian, S., Leissring, M.A., Eckman, E.A., Bertram, L., Eckman, C.B., Tanzi, R.E., Selkoe, D.J. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am. J. Pathol., 2004, 164(4), 1425-1434.
40. Qin, W., Chachich, M., Lane, M., Roth, G., Bryant, M., de Cabo, R., Ottinger, M.A., Mattison, J., Ingram, D., Gandy, S., Pasinetti, G.M. Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J. Alzheimers Dis., 2006, 10(4), 417-422.
41. Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J.T., Puigserver, P., Sadoshima, J., Deng, H., Pedrini, S., Gandy, S., Sauve, A.A., Pasinetti, G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem., 2006, 281(31), 21745-21754.
42. Chen, L., Feany, M.B. [alpha]-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci., 2005, 8(5), 657-663.
43. Okawara, M., Katsuki, H., Kurimoto, E., Shibata, H., Kume, T., Akaike, A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol., 2007, 73(4), 550-560.
44. Alvira, D., Tajes, M., Verdaguer, E., Acuña-Castroviejo, D., Folch, J., Camins, A., Pallas, M. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J. Pineal. Res., 2006, 40(3), 251-258.
45. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J., Young, A.B., Abagyan, R., Feany, M.B., Hyman, B.T., Kazantsev, A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 2007, 317(5837), 516-519.
46. Inoue, H., Jiang, X.F., Katayama, T., Osada, S., Umesono, K., Namura, S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor [alpha] in mice. Neurosci. Lett., 2003, 352(3), 203-206.
47. Gupta, Y.K., Briyal, S., Chaudhary, G. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol. Biochem. Behav., 2002, 71(1-2), 245-249.
48. Gupta, Y.K., Chaudhary, G., Srivastava, A.K. Protective effect of resveratrol against pentylenetetrazole-induced seizures and its modulation by an adenosinergic system. Pharmacology, 2002, 65(3), 170-174.
49. Gupta, Y.K., Chaudhary, G., Sinha, K., Srivastava, A.K. Protective effect of resveratrol against intracortical FeCl3-induced model of posttraumatic seizures in rats. Methods Find Exp. Clin. Pharmacol., 2001, 23(5), 241-244.
50. Kaeberlein, M., McVey, M., Guarente, L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev., 1999, 13(19), 2570-2580.
51. Tissenbaum, H.A., Guarente, L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature, 2001, 410(6825), 227-230.
52. Rogina, B., Helfand, S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. USA, 2004, 101(45), 15998-16003.
53. McBurney, M.W., Yang, X., Jardine, K., Hixon, M., Boekelheide, K., Webb, J.R., Lansdorp, P.M., Lemieux, M. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol. Cell Biol., 2003, 23(1), 38-54.
54. Guarente, L., Picard, F. Calorie restriction-the SIR2 connection. Cell, 2005, 120(4), 473-482.
55. Koubova, J., Guarente, L. How does calorie restriction work? Genes Dev., 2003, 17(3), 313-321.
56. Martin, B., Mattson, M.P., Maudsley, S. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res. Rev., 2006, 5(3), 332-353.
57. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Chung, P., Kisielewski, A., Zhang, L.L., Scherer, B., Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425(6954), 191-196.
58. Valenzano, D.R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L., Cellerino, A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol., 2006, 16(3), 296-300.
59. Picard, F., Guarente, L. Molecular links between aging and adipose tissue. Int. J. Obes. (Lond), 2005, 29(Suppl 1), S36-S39.